The World’s First Preventive Vaccine for Type 1 Diabetes
Vactech – Innovations for Health
Revolutionizing
Immune Health with
Breakthrough Vaccines
Vactech is pioneering immunology with groundbreaking vaccines and diagnostics for type 1 diabetes, celiac disease, and enterovirus-related conditions. Since 2001, we’ve pursued impactful research rooted in academic excellence and substantial commercial potential.
"At Vactech, we are committed to leading the development of innovative vaccines. By preventing Coxsackievirus B (CVB) infection, we have a unique opportunity to improve global health by reducing the incidence of type 1 diabetes and CVB-related diseases worldwide. Our mission is to harness biotechnology to create transformative solutions that improve the lives of millions." Tero Välimaa – CEO, Ph.D
Our Team
Globally Recognized Science, Purpose-Driven Innovation
Our renowned scientific founders, recognized globally in immunology and virology, have secured significant international awards being among the world-leading scientists in their field. The strong scientific basis together with Vactech’s patented innovations and strategic alliances creates an important advantage in our mission of translating science to new health improving solutions.
Research & Development
Vactech Develops Modern
Vaccine Technologies
Patents
We Develop and License Vaccines and Novel Technologies for Vaccines and Diagnostics
Vactech is the sole owner of the patents and patent applications covering the preventive type 1 diabetes vaccine. In addition, Vactech’s patents cover antiviral drugs and diagnostic assays for type 1 diabetes enabling the company to build a product family around diabetes prevention and cure. The IPR portfolio includes in addition international patents covering virus-based products to treat and prevent celiac disease.
Stronger Together
Cooperation With
Academic Groups
and Industrial Partners
Vactech collaborates closely with leading international academic institutions and industry partners, adhering strictly to Good Laboratory Practices (GLP) and Good Clinical Practices (GCP). Our strong experience in preclinical and clinical research together with established collaboration networks creates a solid basis for effective development of our assets and conduction of preclinical and clinical trials.
